$14.50
-0.91 (-5.91%)
InterMune, Inc. (NASDAQ:ITMN)
CAPS Rating:
The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.
The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.